Alterations of Sexual and Erectile Functions after Brachytherapy for Prostate Cancer Based on Patient-Reported Questionnaires
Table 1
Patient characteristics.
Variables
Low risk
Medium risk
LDR (41 patients)
HDR (40 patients)
P
LDR (82 patients)
HDR (77 patients)
P
Mean age (range)
63.9 (53–74)
65.1 (54–74)
0.333
66.2 (50–75)
65.8 (53–76)
0.559
T1c
13 (31.7%)
17 (42.5%)
0.433
15 (18.3%)
9 (11.7%)
0.194
T2a
22 (53.7%)
19 (47.5%)
19 (23.1%)
23 (29.9%)
T2b
6 (14.6%)
3 (7.5%)
15 (18.3%)
18 (23.4%)
T2c
0
0
29 (35.4%)
27 (35.0%)
No data
0
1 (2.5%)
4 (4.9%)
0
GS ≤ 6
39 (95.1%)
40 (100%)
0.157
42 (51.2%)
42 (54.5%)
0.675
GS 7
0
0
40 (48.8%)
35 (45.5%)
No data
2 (4.9%)
0
0
0
Mean iPSA (range)
8.2 (4.5–13.6)
8.0 (3.1–11.7)
0.678
9.6 (0.5–15)
9.6 (1.3–18.6)
0.991
HT 0/1
21/20
20/20
0.913
33/49
31/43
0.835
19 Gy/21 Gy
—
22/18
—
26/51
Baseline clinical data of the patients: there was no significant difference in baseline characteristics between the study arms in any of the risk groups according to the chi-squared test (LDR = low-dose-rate brachytherapy; HDR = high-dose-rate brachytherapy; GS = Gleason score; HT = hormone therapy).
